A Pahse 1 Open Label Dose Escalation Trial of QPI-1007 Delivered by Single Intravitreal Injection to Patients with Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Optic Neuropathy (NAJON) (Stratum II)
|Effective start/end date||2/15/10 → 2/14/13|
- Quark Pharmaceuticals, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.